Antitumor Activity of Antimicrobial Peptides Containing CisoDGRC in CD13 Negative Breast Cancer Cells

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Hou, Lei ^a   Zhao, Xinhan ^a   Wang, Pei ^a   Ning, Qian ^a   Meng, Min ^a   Liu, Caigang ^b  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIC ISOARGINYLASPARTYLGLYCYLCYSTEINYLALANYLLEUCYLLYSYLALANYLISOLEUCYLALANYLLYSYLLEUCYLLYSYLLEUCYLLYSYLLYSYLLEUCYLISOLEUCYLLEUCYLALANYLLEUCYLLYSINE; CYCLIC ISOASPARTYLGLYCYLARGININE; CYCLIC ISOASPARTYLGLYCYLARGINYLCYSTEINYLLEUCYLLEUCYLISOLEUCYLISOLEUCYLLYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSYLLYSYLLEUCYLALANYLLYSYLLEUCYLALANYLLYSINE; MICROSOMAL AMINOPEPTIDASE; PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN BCL 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL INVASION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN MOTIF; S PHASE CELL CYCLE CHECKPOINT; TUMOR VASCULARIZATION;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANIMALS; ANTIGENS, CD13; ANTIMICROBIAL CATIONIC PEPTIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL DEATH; CELL LINE, TUMOR; FEMALE; HUMANS; INTEGRIN ALPHAVBETA3; LIVER; LUNG; MICE; MICE, NUDE; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PEPTIDES, CYCLIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84872241048     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0053491     Document Type: Article

References (28)

1. Zhou T, Jia X, Li H, Wang J, Zhang H, et al. (2011) New tumor-targeted nanosized delivery carrier for oligonucleotides: characteristics in vitro and in vivo. Int J Nanomedicine 6: 1527-1534.
2. Gregorc V, De Braud FG, De Pas TM, Scalamogna R, Citterio G, et al. (2011) Phase I study of NGR-hTNF, a selective vascular targeting agent, in combination with cisplatin in refractory solid tumors. Clin Cancer Res 17: 1964-1972.
3. Chen Y, Wu JJ, Huang L, (2010) Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 18: 828-834.
4. Rizzardi GP, Bordignon C, (2009) NGR and isoDGR are separate moieties binding to different receptors. Blood 113: 5366; author reply 5367.
5. Corti A, Curnis F, (2011) Isoaspartate-dependent molecular switches for integrin-ligand recognition. J Cell Sci 124: 515-522.
6. Haier J, Goldmann U, Hotz B, Runkel N, Keilholz U, (2002) Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin Exp Metastasis 19: 665-672.
7. Braun K, Wiessler M, Pipkorn R, Ehemann V, Bauerle T, et al. (2010) A cyclic-RGD-BioShuttle functionalized with TMZ by DARinv "Click Chemistry" targeted to alphavbeta3 integrin for therapy. Int J Med Sci 7: 326-339.
8. Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, et al. (2002) Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 277: 47891-47897.
9. Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, et al. (2010) Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching. J Biol Chem 285: 9114-9123.
10. Hoskin DW, Ramamoorthy A, (2008) Studies on anticancer activities of antimicrobial peptides. Biochim Biophys Acta 1778: 357-375.
11. Curnis F, Sacchi A, Gasparri A, Longhi R, Bachi A, et al. (2008) Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res 68: 7073-7082.
12. Curnis F, Longhi R, Crippa L, Cattaneo A, Dondossola E, et al. (2006) Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J Biol Chem 281: 36466-36476.
13. Spitaleri A, Mari S, Curnis F, Traversari C, Longhi R, et al. (2008) Structural basis for the interaction of isoDGR with the RGD-binding site of alphavbeta3 integrin. J Biol Chem 283: 19757-19768.
14. von Wallbrunn A, Waldeck J, Holtke C, Zuhlsdorf M, Mesters R, et al. (2008) In vivo optical imaging of CD13/APN-expression in tumor xenografts. J Biomed Opt 13: 011007.
15. Zhang Z, Hatta H, Tanabe K, Nishimoto S, (2005) A new class of 5-fluoro-2′-deoxyuridine prodrugs conjugated with a tumor-homing cyclic peptide CNGRC by ester linkers: synthesis, reactivity, and tumor-cell-selective cytotoxicity. Pharm Res 22: 381-389.
16. Shai Y, (1999) Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1462: 55-70.
17. Carraway KL 3rd, Funes M, Workman HC, Sweeney C, (2007) Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol 78: 1-22.
18. Ellerby HM, Arap W, Ellerby LM, Kain R, Andrusiak R, et al. (1999) Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med 5: 1032-1038.
19. Mai JC, Mi Z, Kim SH, Ng B, Robbins PD, (2001) A proapoptotic peptide for the treatment of solid tumors. Cancer Res 61: 7709-7712.
20. Kawamoto M, Horibe T, Kohno M, Kawakami K, (2011) A novel transferrin receptor-targeted hybrid peptide disintegrates cancer cell membrane to induce rapid killing of cancer cells. BMC Cancer 11: 359.
21. van Wijngaarden P, Coster DJ, Williams KA, (2005) Inhibitors of ocular neovascularization: promises and potential problems. JAMA 293: 1509-1513.
22. Sulochana KN, Ge R, (2007) Developing antiangiogenic peptide drugs for angiogenesis-related diseases. Curr Pharm Des 13: 2074-2086.
23. Corti A, Giovannini M, Belli C, Villa E, (2010) Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF. J Oncol 2010: 732680.
24. Ranogajec I, Jakic-Razumovic J, Puzovic V, Gabrilovac J, (2012) Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients. Med Oncol 29: 561-569.
25. Gasparini G, Brooks PC, Biganzoli E, Vermeulen PB, Bonoldi E, et al. (1998) Vascular integrin alpha(v)beta3: a new prognostic indicator in breast cancer. Clin Cancer Res 4: 2625-2634.
26. Law B, Quinti L, Choi Y, Weissleder R, Tung CH, (2006) A mitochondrial targeted fusion peptide exhibits remarkable cytotoxicity. Mol Cancer Ther 5: 1944-1949.
27. Wu J, Jiang Y, Yang W, He Z, Meng S, et al. (2012) Dual function of RGD-modified VEGI-192 for breast cancer treatment. Bioconjug Chem 23: 796-804.
28. Eliceiri BP, Cheresh DA, (1999) The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 103: 1227-1230.